Rhythm Pharmaceuticals (RYTM) News Today

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is receiving mixed signals, although the latest news is generally supportive of the stock. Shares have recently traded below both their 50-day and 200-day moving averages, leaving investor focus on commercial growth and the company’s path toward profitability.

• Positive Sentiment: Japan launch expands IMCIVREE’s commercial opportunity. Rhythm announced the commercial launch of IMCIVREE (setmelanotide) in Japan for patients with acquired hypothalamic obesity. The launch broadens the drug’s geographic reach and could provide an additional source of revenue growth for the company. Rhythm Launches Imcivree In Japan for Acquired Hypothalamic Obesity
• Positive Sentiment: JPMorgan remains bullish despite a modest target reduction. JPMorgan lowered its price target from $146 to $145 but maintained an “overweight” rating. The revised target still implies approximately 65% upside from the referenced share price, signaling that the analyst views the recent pullback as an attractive entry point. JPMorgan Cuts Target for Rhythm Pharmaceuticals Stock to USD 145.00
• Neutral Sentiment: HC Wainwright continues to rate RYTM “Buy” with a $130 target, but its updated estimates were mixed. The firm raised its FY2026 EPS forecast to a loss of $2.28 from a loss of $2.96 and slightly improved its Q3 and Q4 2026 estimates, suggesting better near-term expectations.
• Negative Sentiment: Longer-term profitability forecasts were reduced. HC Wainwright cut its estimates for Q1 through Q3 2027 and lowered its FY2027 forecast to a loss of $0.62 per share from expected earnings of $0.53. The revisions indicate that the timeline to profitability may be longer than previously anticipated, potentially limiting investor enthusiasm despite the Japan expansion.

Overall, the Japan launch and continued bullish analyst ratings provide support, while revised longer-term earnings expectations remain the main risk for RYTM.